secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2024-10-31T23:59:59+00:00
Accession:  0001178670-24-000052
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q3 product revenue $420M (+34%); GAAP EPS -$0.87, guidance reaffirmed
-----------------------------------------------------------------------------

- Global net product revenues $420M, up 34% YoY; TTR (ONPATTRO+AMVUTTRA) $309M, Rare (GIVLAARI+OXLUMO) $111M.
- GAAP net loss $111.6M ($0.87 loss per share) vs. prior-year net income $147.8M ($1.18); Non-GAAP loss $64.2M ($0.50).
- Submitted sNDA in U.S. and Type II Variation in EU for vutrisiran in ATTR-CM using Priority Review Voucher; potential U.S. launch early 2025.
- Positive Phase 1 mivelsiran data in Alzheimer's: >90% sAPPβ lowering after second dose; no new safety signals. Ph2 planned year-end.
- Suspended ALN-KHK development for type 2 diabetes; appointed Robert Hesslein as Chief Legal Officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000117867024000052/0001178670-24-000052-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000117867024000052/alny-20241031.htm
  HTML page:      https://secwatch.observer/filing/0001178670-24-000052

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer